The rarest IPOs in recent months have been in diagnostics, with only three completed so far this year—and two of those could be argued to be more genomics/drug discovery plays than true diagnostics (D
Do device start-ups that receive the highest market caps on IPO deliver the biggest rates of return to private investors? An analysis we've done (see chart below) seems to answer unequivocally yes. We